Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"

Jump to navigation Jump to search
Line 3: Line 3:
==General==
==General==
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal  | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue =  | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref>
*~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.<ref name=pmid28038711>{{Cite journal  | last1 = Herpel | first1 = E. | last2 = Rieker | first2 = RJ. | last3 = Dienemann | first3 = H. | last4 = Muley | first4 = T. | last5 = Meister | first5 = M. | last6 = Hartmann | first6 = A. | last7 = Warth | first7 = A. | last8 = Agaimy | first8 = A. | title = SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. | journal = Ann Diagn Pathol | volume = 26 | issue =  | pages = 47-51 | month = Feb | year = 2017 | doi = 10.1016/j.anndiagpath.2016.10.006 | PMID = 28038711 }}</ref>
*May represent or overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}}
*May represent ''or'' overlap with what is known as ''hepatoid adenocarcinoma of the lung''.{{fact}}


==IHC==
==IHC==
48,448

edits

Navigation menu